218 related articles for article (PubMed ID: 17224700)
1. Hypertrophic cardiomyopathy: a review of etiology and treatment.
Jurynec J
J Cardiovasc Nurs; 2007; 22(1):65-73; quiz 74-5. PubMed ID: 17224700
[TBL] [Abstract][Full Text] [Related]
2. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.
Maron BJ; Ommen SR; Semsarian C; Spirito P; Olivotto I; Maron MS
J Am Coll Cardiol; 2014 Jul; 64(1):83-99. PubMed ID: 24998133
[TBL] [Abstract][Full Text] [Related]
3. Current perspectives in hypertrophic cardiomyopathy with the focus on patients in the Finnish population: a review.
Kuusisto J; Sipola P; Jääskeläinen P; Naukkarinen A
Ann Med; 2016 Nov; 48(7):496-508. PubMed ID: 27460395
[TBL] [Abstract][Full Text] [Related]
4. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy.
Maron MS; Finley JJ; Bos JM; Hauser TH; Manning WJ; Haas TS; Lesser JR; Udelson JE; Ackerman MJ; Maron BJ
Circulation; 2008 Oct; 118(15):1541-9. PubMed ID: 18809796
[TBL] [Abstract][Full Text] [Related]
6. Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices.
Shirani J; Aurshiya R; Elshaikh A; Olenchock SA; Rowin EJ; Maron MS; Maron BJ
Am J Cardiol; 2021 Mar; 142():130-135. PubMed ID: 33279482
[TBL] [Abstract][Full Text] [Related]
7. Use of implantable pacemakers and implantable defibrillators in hypertrophic cardiomyopathy.
Freedman RA
Curr Opin Cardiol; 2001 Jan; 16(1):58-65. PubMed ID: 11124720
[TBL] [Abstract][Full Text] [Related]
8. Hypertrophic cardiomyopathy: a systematic review.
Maron BJ
JAMA; 2002 Mar; 287(10):1308-20. PubMed ID: 11886323
[TBL] [Abstract][Full Text] [Related]
9. Management of hypertrophic cardiomyopathy.
Enriquez AD; Goldman ME
Ann Glob Health; 2014; 80(1):35-45. PubMed ID: 24751563
[TBL] [Abstract][Full Text] [Related]
10. Hypertrophic cardiomyopathy: etiology, diagnosis, and treatment.
Ramaraj R
Cardiol Rev; 2008; 16(4):172-80. PubMed ID: 18562807
[TBL] [Abstract][Full Text] [Related]
11. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
[TBL] [Abstract][Full Text] [Related]
12. [Hypertrophic cardiomyopathy: current aspects and new developments].
Desnos M
Bull Acad Natl Med; 2012; 196(4-5):997-1009; discussion 1009-10. PubMed ID: 23550458
[TBL] [Abstract][Full Text] [Related]
13. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
[TBL] [Abstract][Full Text] [Related]
14. Hypertrophic cardiomyopathy: risk factors for life and living benefits insurance.
Pokorski RJ
J Insur Med; 2002; 34(1):43-60. PubMed ID: 15303593
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM].
Maron BJ; Spirito P
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):297-302. PubMed ID: 19791462
[TBL] [Abstract][Full Text] [Related]
16. Historical perspectives on the implantable cardioverter-defibrillator and prevention of sudden death in hypertrophic cardiomyopathy.
Maron BJ
Card Electrophysiol Clin; 2015 Jun; 7(2):165-71. PubMed ID: 26002383
[TBL] [Abstract][Full Text] [Related]
17. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
18. Update on hypertrophic cardiomyopathy and a guide to the guidelines.
Sen-Chowdhry S; Jacoby D; Moon JC; McKenna WJ
Nat Rev Cardiol; 2016 Nov; 13(11):651-675. PubMed ID: 27681577
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophic cardiomyopathy considerations for the managed care pharmacist.
Taddei-Allen P
Am J Manag Care; 2021 Apr; 27(6 Suppl):S118-S125. PubMed ID: 33861536
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy.
Maron BJ
Circ J; 2010 Nov; 74(11):2271-82. PubMed ID: 20962423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
